JO3703B1 - مشتقات أوكسوبيريدين مستبدلة - Google Patents
مشتقات أوكسوبيريدين مستبدلةInfo
- Publication number
- JO3703B1 JO3703B1 JOP/2016/0136A JOP20160136A JO3703B1 JO 3703 B1 JO3703 B1 JO 3703B1 JO P20160136 A JOP20160136 A JO P20160136A JO 3703 B1 JO3703 B1 JO 3703B1
- Authority
- JO
- Jordan
- Prior art keywords
- oxopyridine derivatives
- substituted oxopyridine
- disorders
- substituted
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
يتعلق الاختراع بمشتقات oxopyridine مستبدلة وبعمليات لتحضيرها، وأيضا باستخدامها لتحضير أدوية لمعالجة و/أو الوقاية من أمراض، بصفة خاصة اضطرابات قلبية وعائية، يفضل اضطرابات تخثرية أو تخثرية انسدادية، وتورم، وأيضا اضطرابات متعلقة بالعين.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15176099 | 2015-07-09 | ||
EP16157350 | 2016-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3703B1 true JO3703B1 (ar) | 2021-01-31 |
Family
ID=56345141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2016/0136A JO3703B1 (ar) | 2015-07-09 | 2016-07-03 | مشتقات أوكسوبيريدين مستبدلة |
Country Status (40)
Country | Link |
---|---|
US (3) | US10421742B2 (ar) |
EP (1) | EP3319956B1 (ar) |
JP (1) | JP6871180B2 (ar) |
KR (1) | KR102596164B1 (ar) |
CN (2) | CN108026072B (ar) |
AU (1) | AU2016289746B2 (ar) |
CA (1) | CA2990901A1 (ar) |
CL (1) | CL2018000039A1 (ar) |
CO (1) | CO2018000113A2 (ar) |
CR (1) | CR20180017A (ar) |
CU (1) | CU24512B1 (ar) |
CY (1) | CY1123996T1 (ar) |
DK (1) | DK3319956T3 (ar) |
DO (1) | DOP2018000004A (ar) |
EA (1) | EA036208B1 (ar) |
EC (1) | ECSP18001308A (ar) |
ES (1) | ES2856554T3 (ar) |
GE (1) | GEP20197046B (ar) |
HK (1) | HK1255045A1 (ar) |
HR (1) | HRP20210459T1 (ar) |
HU (1) | HUE053552T2 (ar) |
IL (1) | IL256556B (ar) |
JO (1) | JO3703B1 (ar) |
LT (1) | LT3319956T (ar) |
MA (1) | MA42376B1 (ar) |
MX (1) | MX2018000076A (ar) |
MY (1) | MY196640A (ar) |
NI (1) | NI201800001A (ar) |
PE (1) | PE20180538A1 (ar) |
PH (1) | PH12018500057A1 (ar) |
PL (1) | PL3319956T3 (ar) |
RS (1) | RS61584B1 (ar) |
SI (1) | SI3319956T1 (ar) |
SV (1) | SV2018005610A (ar) |
TN (1) | TN2018000011A1 (ar) |
TW (1) | TWI717367B (ar) |
UA (1) | UA122341C2 (ar) |
UY (1) | UY36780A (ar) |
WO (1) | WO2017005725A1 (ar) |
ZA (1) | ZA201800826B (ar) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10077265B2 (en) * | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US20190119213A1 (en) * | 2015-03-19 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
IL277240B2 (en) | 2018-03-15 | 2024-01-01 | Bayer Ag | Process for the preparation of two derivatives of 4-{[(2S)-2-{4-[5-chloro-2-(1H-3,2,1-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridine -1-(2H)-yl}butenoyl]amino}-2-fluorobenzamide |
DK3774796T3 (da) | 2018-04-10 | 2022-07-18 | Bayer Pharma AG | Et substitueret oxopyridinderivat |
WO2020007256A1 (zh) | 2018-07-02 | 2020-01-09 | 江苏恒瑞医药股份有限公司 | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 |
AR115870A1 (es) | 2018-07-31 | 2021-03-10 | Sumitomo Chemical Co | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ |
US20220306602A1 (en) | 2018-12-17 | 2022-09-29 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications |
CA3124220A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
CA3124296A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
CA3152667A1 (en) | 2019-09-27 | 2021-04-01 | Shenzhen Salubris Pharmaceuticals Co. Ltd. | Fxia inhibitors and preparation method therefor and pharmaceutical use thereof |
US20230373972A1 (en) | 2020-09-17 | 2023-11-23 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Piperazine derivative, preparation method therefor and use thereof |
CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
CA3212645A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
CR20230431A (es) | 2021-03-09 | 2023-10-27 | Bayer Ag | Formas de dosificación farmacéuticas que comprenden (4S)–24–cloro–4–etil–73–fluoro–35– metoxi–32,5–dioxo–14–(trifluorometil)–32H–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola– 2(1,2),7(1) dibencenaheptafano–74–carboxamida |
WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
CN113666826B (zh) * | 2021-07-30 | 2024-03-26 | 五邑大学 | 一种芳基或杂芳基甲氧基化反应的方法 |
WO2023174399A1 (zh) * | 2022-03-18 | 2023-09-21 | 苏州晶云药物科技股份有限公司 | 取代的氧代吡啶类衍生物的晶型及其制备方法 |
CN116535392B (zh) * | 2023-06-26 | 2023-09-05 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物的制备方法及中间体和应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
CA2428191A1 (en) | 2000-11-07 | 2002-05-30 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
EP1526131A1 (en) | 2003-10-22 | 2005-04-27 | Graffinity Pharmaceuticals Aktiengesellschaft | Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2007131179A1 (en) | 2006-05-05 | 2007-11-15 | Millennium Pharmaceuticals, Inc. | Factor xa inhibitors |
JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
KR102011534B1 (ko) * | 2011-12-21 | 2019-08-16 | 오노 야꾸힝 고교 가부시키가이샤 | 인자 XIa 억제제로서 피리디논 및 피리미디논 유도체 |
US9409908B2 (en) * | 2012-08-03 | 2016-08-09 | Bristol-Myers Squibb Company | Dihydropyridone p1 as factor XIa inhibitors |
US9617259B2 (en) | 2013-03-14 | 2017-04-11 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
WO2014160592A2 (en) * | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
WO2015011087A1 (de) | 2013-07-23 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma |
CA2928867A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
CN116987080A (zh) | 2014-01-31 | 2023-11-03 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
WO2015120777A1 (zh) | 2014-02-14 | 2015-08-20 | 四川海思科制药有限公司 | 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用 |
US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
JP6517925B2 (ja) | 2014-09-24 | 2019-05-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたオキソピリジン誘導体 |
EP3197880B1 (de) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung |
US10077265B2 (en) | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
WO2016046156A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
US10167280B2 (en) | 2014-09-24 | 2019-01-01 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
US10336730B2 (en) * | 2015-08-05 | 2019-07-02 | Bristol-Myers Squibb Company | Substituted glycine derived FXIA inhibitors |
-
2016
- 2016-07-03 JO JOP/2016/0136A patent/JO3703B1/ar active
- 2016-07-05 PE PE2018000035A patent/PE20180538A1/es unknown
- 2016-07-05 CR CR20180017A patent/CR20180017A/es unknown
- 2016-07-05 HU HUE16734672A patent/HUE053552T2/hu unknown
- 2016-07-05 CN CN201680052335.5A patent/CN108026072B/zh active Active
- 2016-07-05 SI SI201631060T patent/SI3319956T1/sl unknown
- 2016-07-05 UA UAA201801270A patent/UA122341C2/uk unknown
- 2016-07-05 GE GEAP201614692A patent/GEP20197046B/en unknown
- 2016-07-05 EP EP16734672.5A patent/EP3319956B1/en active Active
- 2016-07-05 MY MYPI2018700053A patent/MY196640A/en unknown
- 2016-07-05 EA EA201890111A patent/EA036208B1/ru not_active IP Right Cessation
- 2016-07-05 RS RS20210338A patent/RS61584B1/sr unknown
- 2016-07-05 KR KR1020187003576A patent/KR102596164B1/ko active IP Right Grant
- 2016-07-05 MX MX2018000076A patent/MX2018000076A/es unknown
- 2016-07-05 MA MA42376A patent/MA42376B1/fr unknown
- 2016-07-05 DK DK16734672.5T patent/DK3319956T3/da active
- 2016-07-05 ES ES16734672T patent/ES2856554T3/es active Active
- 2016-07-05 CA CA2990901A patent/CA2990901A1/en active Pending
- 2016-07-05 CN CN202110557164.4A patent/CN113292539B/zh active Active
- 2016-07-05 TN TNP/2018/000011A patent/TN2018000011A1/en unknown
- 2016-07-05 CU CU2018000001A patent/CU24512B1/es unknown
- 2016-07-05 JP JP2017568177A patent/JP6871180B2/ja active Active
- 2016-07-05 WO PCT/EP2016/065787 patent/WO2017005725A1/en active Application Filing
- 2016-07-05 AU AU2016289746A patent/AU2016289746B2/en active Active
- 2016-07-05 US US15/742,063 patent/US10421742B2/en active Active
- 2016-07-05 LT LTEP16734672.5T patent/LT3319956T/lt unknown
- 2016-07-05 PL PL16734672T patent/PL3319956T3/pl unknown
- 2016-07-07 TW TW105121492A patent/TWI717367B/zh active
- 2016-07-08 UY UY0001036780A patent/UY36780A/es active IP Right Grant
-
2017
- 2017-12-25 IL IL256556A patent/IL256556B/en active IP Right Grant
-
2018
- 2018-01-04 NI NI201800001A patent/NI201800001A/es unknown
- 2018-01-05 CL CL2018000039A patent/CL2018000039A1/es unknown
- 2018-01-05 DO DO2018000004A patent/DOP2018000004A/es unknown
- 2018-01-05 PH PH12018500057A patent/PH12018500057A1/en unknown
- 2018-01-08 EC ECIEPI20181308A patent/ECSP18001308A/es unknown
- 2018-01-08 SV SV2018005610A patent/SV2018005610A/es unknown
- 2018-01-09 CO CONC2018/0000113A patent/CO2018000113A2/es unknown
- 2018-02-08 ZA ZA2018/00826A patent/ZA201800826B/en unknown
- 2018-11-07 HK HK18114169.6A patent/HK1255045A1/zh unknown
-
2019
- 2019-08-08 US US16/535,120 patent/US11180471B2/en active Active
-
2021
- 2021-03-18 HR HRP20210459TT patent/HRP20210459T1/hr unknown
- 2021-03-26 CY CY20211100269T patent/CY1123996T1/el unknown
- 2021-10-18 US US17/504,243 patent/US20230024752A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500057A1 (en) | Substituted oxopyridine derivatives | |
TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
WO2016046156A8 (de) | Substituierte oxopyridin-derivate | |
PH12020551973A1 (en) | Substituted dihydropyrazolo pyrazine carboxamide derivatives | |
TN2015000370A1 (en) | Trifluormethyl-substituted ring-fused pyrimidines and use thereof | |
PH12016500065A1 (en) | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof | |
CR20210342A (es) | Derivados de oxopiridina sustituidos | |
TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
PH12019500535A1 (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
PH12015502564B1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
WO2015165933A3 (de) | Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen | |
MX2016000037A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
TN2015000523A1 (en) | Substituted benzoxazoles |